Critical Regulatory Updates (2025-2026) GLP-1 Shortage Resolution & Compounding Restrictions The FDA made significant policy changes in 2024-2025 regarding compounded peptide medications: Tirzepatide (Mounjaro/Zepbound): Removed from FDA shortage list: October 2, 2024 Compounding deadline for 503A pharmacies: February 18, 2025 Compounding deadline for 503B facilities: March 19, 2025 Semaglutide (Ozempic/Wegovy): Shortage status resolved: February 21, 2025 Enforcement discretion ended for 503A compounders: April 22, 2025 503B compounders must cease: May 22, 2025 These changes mean that as of 2026, patients will require prescriptions for FDA-approved brand-name versions rather than compounded alternatives
However, surgery for a meniscus tear may be necessary if: The tear created tissue that is impeding normal knee function
Raper DMS, Ding D, Buell TJ et al (2018) Effect of body mass index on venous sinus pressures in idiopathic intracranial hypertension patients before and after endovascular stenting
Common Challenges in Getting Coverage for GLP-1 Medications Even with the right insurance plan, securing coverage for GLP-1 medications can be challenging
When commercial serums advertise 10% peptides, theyre usually referring to 10% of a solution containing only a few milligrams of actual raw peptide by weight
